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causes suppression of cocaine-induced locomotor activity
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Chronic cocaine induces high expression of the brain-speciﬁc Neural-Zinc-Finger transcription factor-2b
(NZF-2b/7ZFMyt1), particularly in the mesolimbic dopaminergic pathway, resulting in a 11-fold increase in
NZF-2b/7ZFMyt1 expression in the Nucleus Accumbens (NAc). Overexpression of this gene in the NAc with a
NZF-2b/7ZFMyt1-expressing lentivirus resulted in N55% decrease in locomotor activity upon chronic cocaine
administration, compared to control animals. In contrast knocking-down the gene in the NAc with
lentiviruses expressing shRNAs against NZF-2b/7ZFMyt1 induced strong hyperlocomotor activity upon
cocaine. Strong inhibition of BDNF is observed upon NZF-2b/7ZFMyt1 expression, concomitant with strong
induction of transcription factors REST1 (RE silencing transcription factor-1) and NAC1, probably leading to
regulation of gene expression by interaction with histone deacetylases. These changes lead to decreased
responsiveness of the animal to the locomotor-activating effects of cocaine, indicating that NZF-2b/7ZFMyt1
expression plays an important role in phenotypic changes induced by the drug.
Introduction
Drugs of abuse alter synaptic strength and induce long-term
synaptic plasticity in the brain's reward system (Nestler, 2000). This
constitutes the cellular mechanism that directly underlies addictive
behaviors long after drug exposure (Conrad et al., 2008; Lüscher and
Bellone, 2008). Identiﬁcation of drug-induced alterations in gene
expression and gene regulation is therefore key to understanding
molecular adaptations underlying addiction. Drug-evoked plasticity
has been reported in the ventral tegmental area (VTA), the nucleus
accumbens (NAc) and the prefrontal cortex (Nestler, 2000). However
only very few transcription factors (NAC1, CREB and delta-FosB) (Cha
et al., 1997; Mackler et al., 2000; Kalivas et al., 1999; McClung et al.,
2004) have been implicated as of today in gene regulation in the
context of drug-induced plasticity. A further screening for transcrip-
tion factors related to chronic cocaine administration revealed that a
brain speciﬁc transcription factor, Neural zinc ﬁnger transcription
factor 2b (NZF-2b) may play a key role. NZF-2b, also designated as 7
zinc ﬁngerMyelin Transcription Factor-1 (7ZFMyt1), is expressed both
in neurons and also in oligodendrocytes, where it tightly regulates
myelin-speciﬁc gene expression of proteolipid proteins PLP1, MAL2,
MAG (Kim and Hudson, 1992; Strausberg et al., 2003; Nielsen et al.,
2004). NZF-2b/7ZFMyt1 is a member of a neural-speciﬁc transcription
factor gene family (Kim and Hudson, 1992; Strausberg et al., 2003),
comprised of three Zn-ﬁnger genes [Myt1, Myt1L (Myt1-Like) and
NZF3] that are expressed predominantly in the developing CNS. Both
Myt1 and Myt1L proteins reside in distinct domains within the
neuronal and oligodendrocyte nuclei, expressed as discrete patterns
(Armstrong et al. 1995; Kim et al., 1997) and they interact with the co-
repressor Sin3B and actively recruit HDAC1 and HDAC2 to speciﬁc
genes (Romm et al., 2005). The NZF-2/Myt1 comprises two isoforms,
the poorly expressed NZF-2a/Myt1 (6-zinc ﬁnger form) and the
predominant NZF-2b/7ZFMyt1 (7-zinc-ﬁnger form), located on
chromosome 20 and 2 of human and mouse, respectively (Nagase et
al., 1998; Kikuno et al., 1999; Matsushita et al., 2002; Deloukas et al.,
2002; Nielsen et al., 2004). But the role of these two isoforms in
neurons is poorly known.
In the present study we show that cocaine administration induces
high expression of NZF-2b/7ZFMyt1 particularly in the mesolimbic
dopaminergic pathway and that its overexpression in the NAc results
in signiﬁcant hypolocomotor activity upon cocaine administration,
whereas NZF-2b/7ZFMyt1 knock-down induces hyperlocomotor
activity. Furthermore, increased expression of NZF-2b/7ZFMyt1 also
induces differential expression of other genes, possibly resulting in
regulation of downstream genes by epigenetic modiﬁcation. Togeth-
er these data points to the relevant role of NZF-2b/7ZFMyt1 in
regulatory mechanisms of genes related to chronic cocaine
administration.
Abbreviations: CPU, caudate putamen; DA, Dopamine; GFP, green ﬂuorescent
protein; HEK293T, human embryonic kidney 293T cells; NAc, nucleus accumbens; qRT-
PCR, quantitative real-time polymerase chain reaction; shRNA, short hairpin RNA;
siRNA, small interference RNA; VTA, ventral tegmental area; TFBSm, transcriptional
factor binding site modules; BDNF, brain derived neurotrophic factor; REST, RE1-
silencing transcription factor 1; MECP2, methyl-cytosine binding protein; HDAC,
histone deacetylase; BDNF, brain derived neurotrophic factor.
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Experimental procedures
Animal handling
All animal experiments were carried out in accordance with
guidelines and regulations for Animal Experimentation, BAG, Bern,
Switzerland. Male Wistar rats weighing 250–300 g (BRL, Fillingsdorf,
Switzerland) were used for all the experiments. The animals were
housed in groups (four per cage) in clear plastic cages with wire
grid lids. The animals were kept on a 12-h light/dark cycle (lights off
at 07.00 h), with access to food and water ad libitum. For doxy-
cycline treatment, animals were maintained with 0.02% doxycy-
cline (Sigma) and 5% sucrose supplemented in water. During the
gene overexpression period, animals were maintained only with 5%
sucrose.
Computational promoter analysis
Promoter analysis was performed by computational methods
using softwares available in the public domain as well as promoter
analysis tools from Transfac (http://transfac.gbf.de/) and Genomatix
(http://www.genomatix.de/). Genomic sequences 3000 bps upstream
of the transcription start site of a large set of selected genes were
retrieved from Eukaryotic Promoter database (http://www.epd.isb-
sib.ch/) and the highest scoring putative functional transcription
factor binding site modules (TFBSm) were chosen based on stringent
orthologous species conservation constraints. Genes were chosen
based on evident implication in cocaine administration by literature
knowledge. For the computational prediction of MYT1 binding sites in
target gene promoters, the software utilizes the MYT1 matrix family
with an optimized matrix threshold of 0.75 and maintenance of at
least the less stringent requirement of AAGTT motifs (Kim and
Hudson, 1992) to predict a more relevant match. MYT1 matrix has a
re-value of b0.01, i.e., a random expectation of such a binding site is
less than b0.01 matches per 1000 bp. As with most transcription
factors (excluding TATA-box, etc.), MYT1 matrix recognizes symmet-
ric or palindromic sites and have binding sites in both orientations in
promoters or enhancers with a consensus DNA binding site sequence
of at least two AAA(G/C)TTT motifs (Bellefroid et al., 1996).
NZF-2b/7ZFMYT1 lentiviral expression constructs
The lentiviral expression construct of the myelin transcription
factor-1 (NZF-2b/7ZFMYT1) gene was generated from the 7ZFMYT1
plasmid constructs kindly provided by Prof. Armstrong′s lab
(Uniformed Services University of the Health Sciences, Bethesda).
The 7 zinc ﬁnger MYT1 gene coding region along with the Myc tag
(∼3.9 kb) from pMycMyt1-7zf-IRES/RED expression vector was ﬁrst
digested with EcoR I and sub-cloned into pDRIVE vector (QIAGEN).
7ZFMYT1 gene ORF was then digested with SnaB I and Xho I from
pDRIVE and cloned into the lentiviral vector pTK-431 using Hpa I and
Xho I sites that express the gene of interest under control of a Tet-Off
promotor. The clones were veriﬁed by conventional methods. The
green ﬂuorescent protein (GFP) expressing lentiviral vector pTK433
(Bahi et al., 2004; Boyer and Dreyer, 2007) was used as a control
vector.
7ZFMyt1-siRNA lentiviral expression constructs
Three different siRNAs targeting different regions of the NZF-2b
mRNA sequence were constructed to silence NZF-2b/7ZFMyt1
expression in vitro and in vivo. The following targets within the
NZF-2b mRNA sequence were selected, based on Hannon's design
criterion (http://katahdin.cshl.org:9331/RNAi/html/rnai.html): ﬁrst
target: bp 1127–1145; second target: bp 2239–2268 and third target:
bp 3487–3507. To each oligonucleotide, a Xho I restriction site was
added at 3′ and a U6-3′-speciﬁc 10mer at 5′. Using the pSilencer 1.0-
U6 (Ambion, UK) as a template and a U6 promoter-speciﬁc forward
primer containing BamHI restriction site (5′-GCG GAT CCC GCT CTA
GAA CTA GTG C-3′), each siRNA target was added to the mouse U6
promoter by PCR, using the following PCR program: 120s at 93 °C
(initial denaturation) followed by 35 cycles (45 s at 92 °C, 45s at 64 °C
and 45 s at 72 °C) in 5% dimethyl sulphoxide (Sigma, Switzerland).
The PCR product was directly ligated into pDRIVE vector from QIAGEN
PCR Cloning Kit (QIAGEN). The shRNA insert along with the U6
promoter was then digested with BamHI and Xho I, sub-cloned into
similar sites in the lentiviral vector pTK-431, and sequenced to verify
the integrity of each construct.
Lentivirus production
The lentiviral vector expression plasmids (either pTK431-
7ZFMyt1, pTK433-GFP or pTK431-U6-7ZFMyt1-siRNAs), along with
the packaging construct plasmid pΔNRF and the envelope plasmid
pMDG-VSV-G were co-transfected into human embryonic kidney
(HEK) 293T cells to produce the viral particles (Bahi et al., 2004; Boyer
and Dreyer, 2007). The viral titers were determined by p24 antigen
measurements (KPL, USA). For the in vivo experiments, the different
viral stocks were matched for viral particle content and used at
0.2 mg/mL of p24.
Cocaine administration
Rats (n=8) were given single daily i.p. injection of 15 mg/kg
cocaine-HCl for a period of 15 days. Control animals received 0.9%
saline i.p. injections under the same schedule (Bahi et al., 2004; Boyer
and Dreyer, 2007). All animals were sacriﬁced by decapitation 24 h
after the last injection and the brains were removed and stored
rapidly in TRIzol reagent (Invitrogen).
Stereotaxic surgery
Stereotaxic surgery and lentiviral injection were performed
according to previous publications (Bahi et al., 2004; Boyer and
Dreyer, 2007). Rats were anesthetized with ketamine-xylazine
(10 mg/kg and 0.1 mg/kg) administered i.p. Animals were bilaterally
injected into the NAc with 2 μL of concentrated lentiviral expression
system stock (0.2 mg/mL of p24, corresponding to 8×109 IU/mL). The
injections were performed bilaterally at the following coordinates, as
calculated from bregma and the dura mera: anterior +1.4; lateral±
1.2; ventral −6.8 (Paxinos & Watson, 1998).
Open ﬁeld locomotor activity behavioral experiment
Four groups of animals (n=9)were used for the open ﬁeld cocaine
induced locomotor activity monitoring experiment. The ﬁrst group
was stereotaxically injected with 2 μL of Lenti-GFP (controls); the
second group was injected with 2 μL of Lenti-7ZFMyt1; the third
group was injected with 2 μL of a mix of all three Lenti-7ZFMyt1-
siRNAs; and the fourth group was injected with 2 μL Lenti-
7ZFMyt1together with 2 μL of a mix of the three Lenti-7ZFMyt1-
siRNAs. 7−12 days after stereotaxic surgery, locomotor activity was
monitored in daily sessions in 43.2×43.2 cm MED-OFA-RS cages
(MED Associates, USA) during the dark cycle, according to previously
published procedures (Bahi et al., 2004; Boyer and Dreyer, 2007).
Animals were injected daily with cocaine i.p. and were fed without
doxycycline for 5 days (Session A), then fed doxycycline for 7 days
(Session B), and ﬁnally fed without doxycycline for 7 days (Session C).
Locomotor activity was recorded on days 1–5, 8–12 and 15–19; over
the 2-day periods between sessions – necessary for full doxycycline-
mediated switch of ectopic NZF-2b/7ZFMyt1expression – no mea-
surements were performed (Table 1). Prior to each locomotor activity
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measurements, the animal was injected with 0.9% saline, and placed
into the activity-monitoring cage for a 15-min baselinemeasurement.
After this 15-min period, the session automatically paused for a few
seconds and, during this interval, each subject received cocaine-HCl
(Sigma, 15 mg/kg, i.p.) and was then placed back into the locomotor
activity-monitoring cage for a further 60 min. Statistical evaluation of
behavioral analysis was performed according to previous publications
(see Bahi et al., 2004; Boyer and Dreyer, 2007). At the end of the third
session (Session C) half of the animals were sacriﬁced (Table 1). The
other half were switched back on doxycycline for 48 h then killed. All
animals were killed by decapitation. During this switch period,
animals were given continuous daily administration of cocaine. All
groups were sacriﬁced 24 h after the last cocaine injection. Brains
were used for either immunohistochemistry or quantitative real-time
PCR.
Total RNA isolation
Rat brain parts, micro-dissected from cocaine and saline treated
animals, or HEK-293 cells infected with lentivirus for gene expression
were homogenized in TRIzol reagent (Invitrogen), followed by RNA
isolation using chloroform extraction and isopropanol precipitation.
After being washed with 70% and 100% (v/v) ethanol, RNA pellets
were dissolved in DEPC-treated H2O. Quality and integrity of the RNA
was analyzed and quantiﬁed accurately by a Bioanalyzer and 2%
agarose gel. All RNA samples were stored at −70 °C.
NZF-2b/7ZFMYT1 transcript quantiﬁcation by real-time quantitative
PCR
RNA from cocaine and saline-treated animal brain parts were
reverse transcribed using M-MLV Reverse Transcriptase (Promega).
2 μg of RNA from each sample was reverse transcribed at 42 °C for
30min with 1 μg of oligo(dT) or speciﬁc primers, 5 ﬁrst strand buffer,
100 mM DTT, 10 mM dNTP, RNAsin (Invitrogen) and M-MLV. cDNAs
were checked for their optimum dilution in subsequent real-time
PCR reactions. Primer sets for rat NZF-2b/7ZFMyt1, β-actin or cyclophilin
were designed to amplify 100–200 bp products, using PRIMER3 software:
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). PCR reac-
tionmixtures included cDNAs in optimum dilution, the SYBR-Green
qPCR Master mix (BioRad, Reinach, Switzerland), 10 μM primers, in
a total reaction volume of 20 μl. Expression proﬁling was done with
dissociation curves using iCycler (BioRad, Reinach, Switzerland).
Cycling parameters were 95 °C for 4 min followed by 40 cycles of
20 °C/s temperature transition rate up to 95 °C (30s), 62 °C (45 s),
followed by melting curve analysis. All reactions were performed
in triplicates, with reference dye normalization (β-actin or
cyclophilin RNA), and the median Ct (cycle threshold) value was
used for analysis. To determine the linearity and detection limit of
the assay, cDNA samples were ampliﬁed for successive 10-fold
dilutions in a series of real-time PCRs, using a duplicate assay on
each dilution, so that the correlation coefﬁcient could be calculated
from the standard curve of Ct values. Comparisons were made
between cocaine and saline groups. Signiﬁcance was calculated
using two-way ANOVA followed by Bonferroni post hoc tests
and the level of statistical signiﬁcance was set at Pb0.001. Data
were expressed as means±SEM. The ΔCt for each candidate was
calculated as: ΔCt=[Ct (candidate) − Ct (cyclophilin or β-actin)].
The relative abundance of each target can be calculated as the
ratio between treated and untreated samples (Bahi et al., 2004;
Boyer and Dreyer, 2007). The PCR reaction was evaluated by
melting curve analysis and by checking the PCR products on 2%
agarose gel.
The following primer sets were used for ampliﬁcation: 7ZFMYT1:
forward 5′-GCA GAC CTC AGT TGT CCT ACC-3′ and reverse 5′-CTT GGA
TAC CAG GTG CTC AG-3′; cyclophilin: forward 5′-GTG AGA AGG GCT
TTG GCT AC-3′ and reverse 5′-TTC TCG TCA GGA AAG CGG-3′; β-actin:
forward 5′-AGC CAT GTA CGT AGC CAT CC-3′ and reverse 5′-CTC TCA
GCT GTG GTG GTG AA-3′; BDNF: forward 5′-GGT TCG AGA GGT CTG
ACG AC-3′ and reverse 5′-CAA AGG CAC TTG ACT GCT GA-3′; REST1:
forward 5′-CGA GTT GAT GCC TGT TGG AGA C-3′ and reverse 5′-TGC
TTC AAA TAC GGG CTG GG-3′; NAC1: forward 5′-GCT CTT CCT GAG
CAG GTC GT-3′ and reverse 5′-GTG CCT GTC ACA AGC TCC AG-3′.
Immunohistochemistry
To check the expression of NZF-2b/7ZFMyt1 after lentiviral
injections, rats were decapitated, brains were quickly removed,
immediately frozen in isopentane (at −30 °C for 3 min) and kept at
−25 °C. Coronal sections were cut at 14 μm in a cryostat and placed on
gelatinized glass slides, air-dried at room temperature for 20 min and
kept at −25 °C until further processing.
Brain sections were ﬁxed for 10 min in cold acetone and washed
three times in 1×phosphate-buffered saline (PBS). Non-speciﬁc
binding sites were blocked by incubating slices for 1 h in 1×PBS
containing 1% bovine serum albumin, 1% Triton X-100 and 3% normal
goat serum. Sections were then incubated overnight at 4 °C with
primary antibodies speciﬁcally against either endogenous NZF-2b/
7ZFMyt1 (with rabbit polyclonal anti-MYT1 antibody; 1:15; Sigma
prestige antibodies HPA006303) or against Myc for ectopic Myc-
tagged protein (using either mouse monoclonal anti-Myc tag
antibody, Sigma M5546, 1:200 or rabbit polyclonal anti-Myc-tag
antibody; 1:1000; Abcam ab9106) or against NeuN (with mouse
monoclonal anti-neuronal-nuclei, MAB 377, Chemicon, 1:5000) or
against GFAP (anti-glial ﬁbrillary acidic protein (astrocyte marker),
Abcam, ab10062, 1:1000). Antibodies were diluted in 1×PBS contain-
ing 0.1% Triton X-100 and 1% normal goat serum. Thereafter, slices
were washed three times in 1×PBS, and incubated for 2 h in the
secondary antibody (either Texas red-conjugated goat anti-rabbit
immunoglobulin G, 1:5000; or FITC-conjugated goat anti-mouse IgG,
1:5000; or HRP-conjugated goat anti-rabbit, 1:5000) in 1×PBS
containing 0.1% Triton X-100. The sections were coverslipped with a
medium containing glycerol in PBS (AF1mounting solution, Citiﬂuor).
For double staining experiment with NeuN, the slices were ﬁrst
treated with anti-Myc or anti-MYT1 primary and secondary antibody
followed by treatment with NeuN primary and secondary antibody.
For double staining experiments with Hoechst 33342 (1:1500, Sigma,
Steinheim, Germany) nuclei were stained by 30-min incubation.
Negative controls included omission or substitution of primary
antibodies.
Table 1
Experimental protocol for each group of animals used in open ﬁeld locomotor activity experiment.
Days 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Sessions A Switch B Switch C Switch or Sacriﬁce
Doxycycline treatment - - - - - + + + + + + + - - - - - - - - + + + +
Activity measurement √ √ √ √ √ × × √ √ √ √ √ × × √ √ √ √ √ × × × × ×
Sacriﬁce n= 5 of
each group
rest (n= 4)
of each group
At the end of the experiment animals are sacriﬁced and brain tissues were utilized for immunohistochemistry or qRT-PCR (see Materials and methods).
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Fluorescence microscopy was performed to observe the stained
sections using a multiﬂuorescence microscope (Axioplan 2 imaging;
Zeiss). Fluorophores used (FITC and Texas red) were detected with
the appropriate detecting systems (HAL 100). FITC was excited at
495 nm and was detected through a light path ranging 510–550 nm.
Texas red was exited at 570 nm and was detected through a light
path ranging 600–660 nm. Stained sections were visualized, photo-
graphed using a multichannel camera (Axiocam, Zeiss) combined
with acquisition software (Axiovision system 3.1) and recorded on CD
(Boyer and Dreyer, 2007).
Statistical analysis
For chronic expression proﬁle of 7ZFMyt1, statistical analysis was
done using two-way ANOVA and Student's paired one-tailed t-test
to compare between saline and cocaine treated samples. Two-way
ANOVA was used to compare both lentiviral and drug treatment in
the presence or absence of doxycycline, using GraphPad PRISM
(V3.0, GraphPad, San Diego, CA). For locomotor activity two-way
ANOVA was used, with time as the within-subject factors and lenti-
viral gene expression as the between-subject factors followed by
Bonferroni post hoc tests. Quantitative real-time PCR results were
analyzed by two-way ANOVA, with drug treatment (water vs. doxy-
cycline) as the within-subject factors and lentiviral-mediated gene
expression as the between-subject factors followed by Bonferroni
post hoc tests.
Results
In silico promoter analysis of cocaine modulated genes to identify
putative cocaine responsive transcription factor
In this study, we used in silico promoter analysis of a set of genes
differentially expressed upon cocaine administration to identify
potential candidate transcription factors involved in cocaine
administration (Table S1 and Fig. S1, supplementary material). The
results revealed the potential role of the brain speciﬁc transcription
factor NZF-2b/7ZFMyt1. We have selected a large set of context-
oriented genes, based on extensive literature search implicating
them on cocaine administration pathway. Computational promoter
analysis of these genes (horizontal gene selection) over a span of
N3000 bp up stream of the transcriptional start site (data not
shown) enabled to identify several transcription factors having
putative functional transcriptional factor binding site modules
(TFBSm) in several of the chosen genes. Although the occurrence
of a single transcription factor binding site found by the software
alone does not imply it is functional, functionality is determined by
the sequence context. If a binding site is part of a framework of two
or more sites there is strong evidence that the individual sites may
be functional. Candidates for further functional module analysis
were selected based on stringent conservation parameters, i.e., con-
servation of TFBSm among different genes involved in the same
pathway and across orthologous species (e.g., human, rat, mouse).
For the Myt1 binding site prediction in the gene promoters spanning
N3000 bp upstream of the transcription start site, the known
consensus binding site motif AAA(G/C)TTT (Kim and Hudson, 1992;
Bellefroid et al., 1996) were utilized on both strands of the promoter
and enhancer sequences. Next we checked the transcription factors
with the highest scoring conserved functional modules (predicted)
for speciﬁc expression patterns in the brain, by literature search and
by available microarray data results. Further validation of the
implicated transcription factors from the promoter analysis was
done by quantitative RT-PCR. From our promoter analysis we found
that NZF-2b/7ZFMyt1 has a highly conserved putative TFBSm in
many of the genes analyzed (Table S1, Fig. S1). The fact that NZF-2b/
7ZFMyt1 is a brain and developmental stage speciﬁc transcription
factor gave an indication that NZF-2b/7ZFMyt1 might have a
signiﬁcant role in the regulation of these established cocaine res-
ponsive genes.
Cocaine induces differential expression of the brain speciﬁc transcription
factor NZF-2b/7ZFMyt1 (Neural-Zinc-Finger transcription factor
2b/7ZF-Myelin transcription factor 1) in different brain regions
To assess the function of NZF2b/7ZFMyt1 in cocaine administration,
a group of animals (n= 8) was injected daily 15 mg/kg of cocaine i.p.
over a period of 15 days, and a control group was injected 0.9% saline.
Thereafter animals were sacriﬁced by decapitation and brains were
micro-dissected for RNA isolation to be used for qRT-PCR. Primers
speciﬁc to the 7zf-Myt1 (Nielsen et al., 2004) were used and were
normalized against cyclophilin. The results show that 7zf-Myt1
expression was signiﬁcantly increased following chronic cocaine
administration (Fig. 1; F1,24=971.91, Pb0.0001). A 11-fold up-
regulation of NZF-2b/7ZFMyt1 was observed in the nucleus accum-
bens (NAc) (Pb0.0001), compared to the saline treated control group.
This was correlated with a two-fold up-regulation in the ventral
tegmental area (VTA) (Pb0.05), a very strong induction of about 30-
fold increase in the hippocampus (HIP) (Pb0.0001), compared to
negligible basal level expression, and 2.4-fold increase in the
prefrontal cortex (PFC) (Pb0.05). A slight, but not signiﬁcant down-
regulation was found in the caudate putamen. Other brain regions
analysed (“rest of the brain,” ROB) (Pb0.0001), displayed a 5.5-fold
increase in NZF-2b/7ZFMyt1 expression (Fig. 1; F5,24=100.38,
Pb0.0001). These data correlate with in silico results, which showed
that NZF-2b/7ZFMyt1 displays highly conserved TF binding modules
in many cocaine-modulated genes and thus may be differentially
expressed upon cocaine administration.
Furthermore, a group of animals (n= 8) was injected with four
high doses of cocaine (30 mg/kg i.p.) at 2-h interval within a single
day whereas a control group (n=8) received 0.9% saline under the
same schedule that mimics the drug abuse in humans and allows for
easy assessment of neurobiological changes associated with addiction
(Michna et al., 2002). Quantitative RT-PCR revealed that signiﬁcant
increase in gene expression of NZF-2b/7ZFMyt1 was observed in the
NAc and in the Hip but not in other brain regions examined (data not
shown). Together the NZF-2b/7ZFMyt1 expression proﬁle in these
two different cocaine administration paradigms showing a strong
induction in the expression of NZF-2b/7ZFMyt1 in speciﬁc brain
regions related to the mesolimbic dopaminergic pathway supports
our hypothesis on its role in gene regulation upon cocaine exposure.
Fig. 1. Chronic cocaine administration induces differential expression of the brain-
speciﬁc transcription factor NZF-2b/7ZFMyt1 (Neural-Zinc-Finger transcription factor
2b/7ZF Myelin transcription factor 1) in different brain regions. Quantiﬁcation of NZF-
2b/7ZFMyt1 mRNA levels by qRT-PCR from rats (n= 8) after either chronic cocaine
administration (15 mg/kg/day) or saline (control) (see Methods for details). Expres-
sion levels were calculated relative to the endogenous housekeeping gene cyclo-
philin. ⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001 by Student's paired t-test, and compared
to saline treated samples. VTA: ventral tegmental area; NAc: nucleus accumbens;
CPU: caudate putamen; HIP: hippocampus; PFC: prefrontal cortex; ROB: rest of the
brains.
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NZF-2b/7ZFMyt1 expression in the NAc decreases locomotor activity
upon cocaine administration
To further reveal the implications of NZF-2b/7ZFMyt1 gene
expression in behavior, we constructed a doxycycline-regulatable
lentiviral vector, Lenti-7ZFMyt1, holding the mouse NZF-2b/
7ZFMyt1 cDNA, as well as three non-regulatable lentiviral vectors,
Lenti-7ZFMyt1-siRNA1, Lenti-7ZFMyt1-siRNA2 and Lenti-7ZFMyt1-
siRNA3. The latter are expressing small hairpin RNAs, aimed at
silencing NZF-2b/7ZFMyt1 expression and are speciﬁcally targeted
against different regions of the NZF-2b/7ZFMyt1 mRNA (Materials
and methods). In vitro studies conﬁrmed that Lenti-7ZFMyt1 ex-
pressed NZF-2b/7ZFMyt1 and that the expression could be blocked
efﬁciently and speciﬁcally with Lenti-7ZFMyt1-Sils (data not
shown). These viruses were stereotaxically injected into the shell
part of the NAc and the effects of their expression upon passive
cocaine delivery on locomotor activity were assessed. Of the four
groups of animals (n= 9), one group was injected with the
doxycycline-regulatable Lenti-7ZFMyt1, resulting in local overex-
pression of the gene in absence of doxycycline; a second group was
injected with Lenti-7ZFMyt1 together with a mix of three Lenti-
7ZFMyt1-siRNAs; a third group was injected only with a mix of three
Lenti-7ZFMyt1-siRNAs, inducing local silencing of the gene; the
fourth group was a control group injected with Lenti-GFP (green
ﬂuorescent protein). Behavioral evaluation was performed over a
period of three weeks in three 5-day sessions: session A, no
doxycycline; session B, animals fed doxycycline; then session C, no
doxycycline, recapitulating both local gene expression of session A
and initially observed behavioral manifestations. Chronic cocaine
administration was continued daily throughout each sessions A, B
and C. Between each session, a 2-day period without behavioral
measurement was managed to enable full change in gene expression,
during which animals were also daily injected cocaine. This protocol
enables an accurate behavioral evaluation of the effects of local gene
expression changes on the very same animals (Bahi et al. 2004,
2005a; Bahi and Dreyer, 2005).
Manipulations in the NZF-2b/7ZFMyt1 ectopic expression levels
induced changes in the locomotor stimulant effects of cocaine as
compared to control, GFP expressing group (Figs. 2A and B). When
animals were injected with Lenti-GFP (control), a typical cocaine
induced locomotor activity was observed, that remained unchanged
when animals were fed doxycline (Figs. 2A and B). This was not
surprising as previous work from our lab has shown that GFP
overexpression in the NAc does not affect behavior compared to naive
animals in cocaine induced locomotor activity (Bahi et al., 2004;
2005a; Bahi and Dreyer, 2005; Boyer and Dreyer, 2007). When
animals were injected with Lenti-7ZFMyt1, 50-55% reduction in the
locomotor activity was observed (Figs. 2A and B, F3,240=218.96,
Pb0.0001) under conditions of gene expression, i.e., in the absence of
doxycycline (F14,240=120.30, Pb0.0001). When these animals were
fed doxycycline (session B), inducing down-regulation of ectopic NZF-
2b/7ZFMyt1 expression (F14,240=200.32, Pb0.0001), locomotor
activity was not signiﬁcantly different from the GFP control group
(F3,240=58.92, Pb0.0001) under similar conditions; but removing
doxycycline (session C) restored again the behavior observed during
session A (Fig. 2). The other group of animals, injected with Lenti-
7ZFMyt1-siRNAs – inducing local suppression of endogenous NZF-2b/
7ZFMyt1 expression – displayed a strong (50%) increase of locomotor
activity compared to GFP controls during session A, i.e., in absence of
doxycycline (F3,240=218.96, Pb0.0001), when fed doxycycline, no
signiﬁcant behavioral change was observed in these same animals
compared to controls (F3,240=58.92, Pb0.0001) (as expected,
because Lenti-7ZFMyt1-siRNAs are not doxycycline-regulatable),
and the same behavior was maintained by removing doxycycline in
session C (F3,240=270.22, Pb0.0001). Finally the group of animals –
injected with Lenti-7ZFMyt1 and a mix of three Lenti-7ZFMyt1-
siRNAs – displayed locomotor activity almost comparable to the GFP
control group in sessions A and C (without doxycycline; F3,240=
218.96, Pb0.0001 and F3,240=270.22, Pb0.0001, respectively), except
for the shoulder regions of the curves: NZF-2b/7ZFMyt1 expression
causes immediate response to cocaine injection, manifesting its peak
in locomotor activity signiﬁcantly earlier than the control GFP group.
Upon doxycyline treatment (session B) that inhibits both ectopic and
endogenous NZF-2b/7ZFMyt1 expression, these same animals dis-
played a 25% increase in locomotor activity compared to GFP group
(F3,240=218.96, Pb0.0001) (Figs. 2A and B).
Cocaine-induced behavioral sensitization was well observed for all
groups during session A over the ﬁrst 5 days (Fig. 2C; F4,40=5.57,
P=0.0012). The sensitization was signiﬁcant in the Lenti-GFP and
Lenti-Myt1+Lenti-Myt1-siRNAs groups displaying a 40.5% and ∼50%
increase in locomotor activity over this session compared to 16%
increase in Lenti-Myt1-siRNAs group. Sensitization effect observed in
animals injected with Lenti-Myt1 in the ﬁrst 5 days of cocaine
administration (F3,40=82.85, Pb0.0001) were absent in sessions B
and C. In the rest of the groups, during subsequent session B, only a
modest non-signiﬁcant level of sensitization was observed which was
completely absent in the ﬁnal session C.
Quantiﬁcation of NZF-2b/7ZFMyt1 mRNA levels after in vivo
Lenti-7ZFMyt1 expression in the NAc
To assess whether the behavioral changes observed were related
to NZF-2b/7ZFMyt1 gene expression, animals were sacriﬁced after
the behavioral experiments and NZF-2b/7ZFMyt1 mRNA levels were
tested in the NAc and VTA by qRT-PCR. Lentiviruses have been
injected in the NAc in all animals and mRNA from either the NAc
or the VTA was isolated at the end of the behavioral experiments
(as described in the previous section). As shown in Fig. 3A, animals
injected Lenti-7ZFMyt1 displayed a 4-fold increase in expression
of NZF-2b/7ZFMyt1 in the NAc (F3,16=196.50, Pb0.0001), compared
to GFP control (endogenous expression) in the absence of
doxycycline and a 1.5-fold overexpression in presence of doxycy-
cline, i.e., upon suppression of ectopic NZF-2b/7ZFMyt1 expression
in the NAc (F1,16=104.48, Pb0.0001). The ratios of control genes,
e.g., cyclophilin or β-actin mRNA levels, remained unchanged over
treated, untreated and control animals (data not shown). When
injected with Lenti-7ZFMyt1-siRNAs in the NAc animals displayed a
5.7-fold decrease in NZF-2b/7ZFMyt1 mRNA in the NAc, compared
to GFP controls under all regimens (F3,16=196.50, Pb0.0001). This
was expected as doxycycline blocks ectopic, lentivirus-mediated
NZF-2b/7ZFMYT1 overexpression but not endogenously expressed
NZF-2b/7ZFMYT1, while the NZF-2b/7ZFMYT1 silencers block both
ectopic and endogenous NZF-2b/7ZFMYT1 expression. Finally ani-
mals co-injected Lenti-7ZFMyt1 and a mix of three Lenti-7ZFMyt1-
siRNAs in the NAc displayed expression similar to GFP controls in
absence of doxycycline (F3,16=196.50, Pb0.0001) and a 4.2-fold
decrease over GFP controls under doxycycline regimen
(F1,16=104.48, Pb0.0001). Observation of some expression in
Lenti-7ZFMyt1 treated animals under doxycycline regimen is clearly
attributed to the slight leakiness of the Tet-off system used in our
constructs.
Lentiviral injections into the NAc region lead to infection of the
dopaminergic neurons projecting from the VTA. Retrograde Trans-
port mediated by lentivirus has been amply documented, although
it is far less efﬁcient than, e.g. rabies or EEAV (Kitagawa et al., 2007;
Mukherjee et al., 2007; Osten et al., 2006). Active lentiviral particles
may therefore also be retro-transported to the VTA possibly leading
to the expression of NZF-2b/7ZFMyt1, as observed in previous
studies (Bahi et al., 2008; Boyer and Dreyer, 2007). To check
whether this was the case, expression levels of NZF-2b/7ZFMyt1 in
the VTA were quantiﬁed as mentioned for the NAc region. The
results demonstrate that NZF-2b/7ZFMyt1 indeed is expressed,
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albeit to a lesser level compared to NAc region as shown in Fig. 3B.
In the absence of doxycycline, animals injected with Lenti-7ZFMyt1
in the NAc displayed a 5.1-fold increase in NZF-2b/7ZFMyt1
expression (compared to GFP controls) in the VTA (F3,16=188.48,
Pb0.0001), but with doxycycline treatment this difference is
abolished (F1,16=80.52, Pb0.0001). In contrast animals injected
Lenti-7ZFMyt1-siRNAs in the NAc displayed a 2-fold down-regula-
tion of NZF-2b/7ZFMyt1 expression in the VTA, which was not
modiﬁed by doxycycline regimen. The results from immunohisto-
chemistry studies (below) clearly conﬁrm that the expression seen
in VTA can be attributed to retrograde transport and not to diffusion
of viral particles.
NZF-2b/7ZFMyt1 localizes into the nucleus of the neurons in the NAc
region after lentiviral mediated over expression
The changes in NZF-2b/7ZFMyt1 mRNA expression were further
correlated at the protein level by means of immunohistochemistry
(Fig. 4). Animals treated with Lenti-7ZFMyt1 displayed high level of
expression of NZF-2b/7ZFMyt1 in the NAc. Under the same conditions,
doxycycline treatment induced a strong suppression (N90%) of
ectopic NZF-2b/7ZFMyt1 expression in the NAc (Fig. 4A). This showed
a doxycycline-mediated changes in NZF-2b/7ZFMyt1 expression in
7ZFMyt1-treated animals. GFP-treated animals or animals injected
with Lenti-7ZFMyt1-siRNAs displayed no visible NZF-2b/7ZFMyt1
expression under all regimens, as the anti-Myc-antibody recognizes
only the Myc-tagged, ectopically expressed NZF-2b/7ZFMyt1 protein
and not the endogenous form (Fig. 4A). Since there was little
difference observed between the expression levels of NZF-2b/
7ZFMyt1 mRNA level between different doxycycline regimens in the
control GFP group, it is reasonable to believe that the endogenous
protein levels does not change between the groups, under the same
chronic cocaine treatment. The animals injected with Lenti-7ZFMyt1
together with Lenti-7ZFMyt1-siRNAs displayed lesser NZF-2b/
7ZFMyt1 expression that was fully suppressed under doxycycline
regimen (Fig. 4A).
As NZF-2b/7ZFMyt1 – a known suppressive transcription factor –
displayed inhibitory effects on cocaine sensitivity, we wanted to check
whether this suppression is via its transcriptional function. Immunolo-
calization studies were performed to check whether ectopic NZF-2b/
7ZFMyt1 (Myc-tagged) localizes to nucleus or cytoplasm of the neurons
(Fig. 4B). Double immunostaining with the neuron-speciﬁc marker
NeuN under high magniﬁcation of NZF-2b/7ZFMyt1-expressing neu-
rons shows that 7ZFMyt1-Myc expression appears as speckles within
the nucleus (Fig. 4B), suggestive of an association of NZF-2b/7ZFMyt1
with a function that is spatially segregated into discrete nuclear
domains similar to the sites of active transcription, which corresponds
to the data obtained from immunostudies by Nielsen et al., 2004.
Similar results were observed with antibody against native NZF-2b/
7ZFMyt1 protein (Fig. 4C), which will recognize both the endogenous
and ectopically expressed NZF-2b/7ZFMyt1 protein. Double immunos-
taining of ectopicMyc-tagged 7ZFMyt1 (with anti-Myc antibodies) and
GFAP (with anti-GFAP antibodies) shows that ectopic NZF-2b/7ZFMyt1
is absent in GFAP-positive cells and is poorly co-localized in astrocytes
(Fig. 4D). Furthermore the nuclear localization was conﬁrmed by
double staining using non-speciﬁc nuclei staining Hoechst-33342
and anti-Myt1 antibody, which shows that NZF-2b/7ZFMyt1 ex-
pression is restricted to cell type-speciﬁc nuclei (Fig. 4E), in this case
neuronal as conﬁrmed with NeuN staining. Double staining for anti-
Myt1 and anti-Myc (Fig. 4F), conﬁrmed the colocalization and
speciﬁcity of the antibodies used. The restricted, lentiviral mediated
expression of ectopic NZF-2b/7ZFMyt1 within the NAc is clearly
visualized with DAB (brown) staining and low resolution light
microscopy (Fig. 4G), using anti-Myc antibody which localizes
within the NAc region, identiﬁed by the proximity to aca (Commis-
sure anterior Anterior part).
Fig. 3. In vivo expression of NZF-2b/7ZFMyt1 mRNA after injection of lenti-7ZFMyt1
and/or lenti-7ZFMyt1-siRNAs in the NAc. (A) NZF-2b/7ZFMyt1 expression in the NAc;
(B) NZF-2b/7ZFMyt1 expression in the VTA. Quantiﬁcation by qRT-PCR of NZF-2b/
7ZFMYT1 mRNA transcript levels, either in the NAc (A) or in the VTA (B), from rats
(n= 9) bilaterally injected into the NAc. Animals were stereotaxically injected with
either lenti-7ZFMyt1 alone; lenti-7ZFMyt1 in combination with amix of the three lenti-
7ZFMyt1 siRNAs; a mix of the three lenti-7ZFMyt1 siRNAs alone; or lenti-GFP (see
Methods for details). Samples were retrieved after the end of the behavioral analysis
(locomotor activity), either from animals fed without doxycycline or from animals fed
doxycycline. Animals were sacriﬁced by decapitation 24 h after the last injection, the
NAc region wasmicro-dissected and used for total RNA isolation, cDNA preparation and
qRT-PCR. Expression levels were calculated relative to cyclophilin-D or β-actin.
⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001 represent values signiﬁcantly different from lenti-
GFP injected rats, and +Pb0.05; ++Pb0.01; +++Pb0.001 represent values signiﬁcantly
different from lenti-7ZFMyt1 injected rats, by two-way ANOVA, Bonferroni post hoc
tests.
Fig. 2. In vivo effects of NZF-2b/7ZFMyt1 overexpression or silencing in the NAc on cocaine-induced locomotor activity. Values represent means ±SEM of 5 days (n= 9). (A)
Locomotor activity: Four groups (n= 9/group) were used, Lenti-MYT1 alone; Lenti-MYT1 together with Lenti-MYT1-shRNAs; a third group injected with only Lenti-MYT1-shRNAs;
control animals injected with Lenti-GFP. All animals were bilaterally injected into the NAc. Seven days post-operation, Session A (no doxycycline) was initiated and animals were
chronically administered 15mg/kg cocaine each day for ﬁve consecutive days. Prior to eachmeasurements, the animal were injected with 0.9% saline, and placed into the monitoring
cage for a 15-min baseline measurement. Cocaine (15 mg/kg, i.p.) was then injected and the animal returned to the cage for further 60 min and locomotor activity was monitored.
Each datapoint represents the average over all activity generated by the groups in each session. (B) Total locomotor activity: Total locomotor activity over the whole session for each
animal group is calculated from the panels in (A). (C) Cocaine-induced behavioral sensitization. Sensitization curves, calculated as total distance traveled each day for each group
during the sessions A, B or C. Session A: animals fed without doxycycline; Session B: animals fed doxycycline in the drinking water; Session C: animals fed without doxycycline (see
Methods). Over-expression of NZF-2b/7ZFMyt1 in the NAc induced a signiﬁcant decrease both on cocaine-induced locomotor activity peak (A) and total locomotor activity (B) that
could be brought back to control levels by doxycycline treatment. Silencing of NZF-2b/7ZFMyt1 leads to an increase in cocaine-induced locomotor activity. Signiﬁcant cocaine-
induced sensitization was observed (C) in all the groups after chronic cocaine delivery period over the initial 5 days of the locomotor activity measurements (Session A). ⁎Pb0.05,
⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 represent values signiﬁcantly different from Lenti-GFP infected rats; #Pb0.05, ##Pb0.01, ###Pb0.001 represent values signiﬁcantly different from Lenti-
7ZFMyt1 injected rats; two-way ANOVA, Bonferroni post hoc tests.
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NZF-2b/7ZFMyt1 overexpression in the NAc induces changes in the
expression levels of REST1, NAC1 and BDNF
Changes in NZF-2b/7ZFMyt1 expression might result in cocaine-
mediated changes in down-stream signaling. Analysing all the
possible genes modulated upon NZF-2b/7ZFMyt1 overexpression is
beyond the scope of this study. Here, we focused on the BDNF (brain
derived neurotrophic factor), REST1 and the transcription factor
NAC1, a well studied suppressor of cocaine sensitivity (Mackler et al.,
2000). As a matter of fact, it has been shown that NZF-2b/7ZFMyt1
inhibits the expression of MeCP2 (Liu et al., 2009), which in turn may
represses REST1 and CoREST expression (Abuhatzira et al., 2007).
Furthermore expression of REST and CoREST may inhibit BDNF
expression levels, as shown in Rett syndrome (Abuhatzira et al.,
2007). Also NZF-2b/7ZFMyt1 itself has putative conserved functional
binding site modules in BDNF. Together this suggested that NZF-2b/
7ZFMyt1 overexpression might lead to induction of REST1 expression
and probably inhibition of BDNF levels. To check the hypothesis, the
expression of these effectors was further tested in relation to NZF-2b/
7ZFMyt1 expression (Fig. 5).
We observed that REST1 expression is induced signiﬁcantly (ca.
2.5-fold) upon chronic cocaine administration, compared to saline-
treated animals (data not shown). Furthermore, we observed that
REST1 displays signiﬁcant expression changes that correlate with
expression changes of NZF-2b/7ZFMyt1 (Fig. 5A). In the different
lentivirus-treated animal groups, doxycycline regimen that modiﬁes
NZF-2b/7ZFMyt1 expression also affects REST1 expression (Fig. 5A;
F3,16=90.67, Pb0.0001). In the absence of doxycycline a 1.8-fold
induction of REST1 was observed in Lenti-7ZFMyt1 treated animals,
compared to GFP-treated animals, where REST1 is unaltered even in
the presence of doxycycline (Fig. 5A; F3,16=289.42, Pb0.0001). Local
suppression of NZF-2b/7ZFMyt1 expression in Lenti-siRNAs treated
animals results in basal REST1 expression level in the presence or
absence of doxycycline, comparable to saline treated naive animals.
Under doxycycline regimen the levels of REST1 expression dropped
signiﬁcantly in both the Lenti-7ZFMyt1 treated group and the group
treated with Lenti-7ZFMyt1 together with the three Lenti-7ZFMyt1-
siRNA (Fig. 5A). No change was observed in the group treated with
Lenti-7ZFMyt1-siRNAs alone and or in the Lenti-GFP group. Under
these conditions, Lenti-7ZFMyt1 treated animals display 40% reduc-
tion in REST1 expression compared to GFP-treated controls (Fig. 5A;
F1,16=250.03, Pb0.0001). Doxycycline regimen did not modify the
REST1 expression proﬁle of the Lenti-7ZFMyt1-siRNA group (as
expected, since expression of siRNAs was not regulatable).
NZF-2b/7ZFMyt1 expression in the NAc strongly induces NAC1
in that brain region, and doxycycline regimen that modiﬁes NZF-
2b/7ZFMyt1 expression in lentivirus-treated animals also affects
NAC1 expression (Fig. 5B F3,16=37.91, Pb0.0001). In the absence of
doxycycline, 7ZFMyt1-overexpressing animals display a 2.4-fold inc-
rease in NAC1 expression compared to GFP-treated controls (Fig. 5B;
F3,16=55.47, Pb0.0001). Doxycycline did not affect NAC1 expression
proﬁle in lenti-GFP-treated animals, but in Lenti-7ZFMyt1 treated
animals it induced a suppression of NAC1, by suppressing local ectopic
expression of NZF-2b/7ZFMyt1. In contrast, suppression of NZF-2b/
7ZFMyt1 in animals treated with Lenti-7ZFMyt1-siRNAs results in
2-fold decreased expression of NAC1 compared to Lenti-GFP group
under the same cocaine treatment conditions, and was not signiﬁ-
cantly modiﬁed under doxycycline regimen (Fig. 5B; F1,16=118.51,
Pb0.0001).
Furthermore NZF-2b/7ZFMyt1 induction in cocaine-treated ani-
mals leads to potent inhibition of BDNF. In Lenti-7ZFMyt1 treated
animals we observed a strong inhibition of BDNF mRNA levels
(Fig. 5C; F3,24=35.34, Pb0.0001), the lenti-7ZFMyt1 treated group
yielding a 3.8 fold decreased expression in the absence of doxycycline
(F3,24=200.93, Pb0.0001), compared to lenti-GFP group (Fig. 5C). As
observed in NAC1 and REST1, doxycycline treatment did not affect
the expression level of BDNF in lenti-GPF and Lenti-7ZFMyt1-siRNAs
only groups; but in the Lenti-7ZFMyt1 and Lenti-7ZFMyt1+Lenti-
7ZFMyt1-siRNAs groups an increase in BDNF expression was
observed (Fig. 5C; F1,24=78.15, Pb0.0001). Interestingly suppression
of NZF-2b/7ZFMyt1 (in animals treated with Lenti-7ZFMyt1-siRNAs
alone) results in 1.8-fold increased expression of BDNF compared to
Lenti-GFP group under the same cocaine treatment conditions.
Discussion
Chronic abuse of cocaine causes neuroadaptive changes in the
Nucleus Accumbens (NAc) and the Ventral Tegmental Area (VTA)
(Nestler, 2000). Our data show that cocaine induces elevated
expression of NZF-2b/7ZFMyt1 (Neural-Zinc-Finger transcription
factor 2b/7-Zinc Finger Myt1), particularly in the mesolimbic
dopaminergic pathway, resulting in an 11-fold increase in the nucleus
accumbens and a 30-fold increase in the hippocampus. This is
suggestive of a role for NZF2b/7ZFMyt1 in drug-associated behavior
and reward, and also maybe in learning and memory and cue-related
behavior. However a clariﬁcation of that role needs further investi-
gations. NZF-2b/7ZFMyt1 is normally found in neural precursors and
in some subpopulations of mature neurons (Bellefroid et al. 1996; Kim
et al. 1997), and it is also expressed in developing oligodendrocytes
(Armstrong et al. 1995). NZF-2b/7ZFMyt1 interacts with three iso-
forms of Sin3B, which mediates transcriptional repression by binding
to histone deacetylases HDAC1 and HDAC2 (Romm et al., 2005).
Furthermore, we found that localized expression changes of
NZF-2b/7ZFMyt1 in the NAc signiﬁcantly affect cocaine-mediated
behavior. Chronic cocaine administration can produce tolerance or
sensitization to locomotor activating effects, depending on the
Fig. 4. Immunohistochemistry of endogenous and of ectopic NZF-2b/7ZFMyt1 in the NAc. Immunohistochemistry was performed after in vivo lentivirus delivery into the NAc
according to the coordinates described in the methods section. Animals used for behavioral analysis were fed either 5% sucrose or 5% sucrose⁄0.02% doxycycline. Animals were
sacriﬁced at the end of behavioral analyses; brains were dissected out and processed for immunohistochemistry (see Methods). (A) Low-magniﬁcation images (40×) of NZF-2b/
7ZFMyt1 expression (Myc-tagged) in animals fed without doxycycline (left) and in animals fed doxycycline (right). The four panels represent the four lentivirus-injected groups.
Labeling was performed with antibodies against Myc-tag epitope of the ectopic NZF-2b/7ZFMyt1 protein (green) and visualized with 40× magniﬁcation under a ﬂuorescence
microscope (scale bar, 20 μm). (B) Sections were double immunostained with antibodies against NeuN (red) andwith anti-Myc antibodies for detectingMyc-tagged, ectopic NZF-2b/
7ZFMyt1 protein (green) and visualized with 63× magniﬁcation under a ﬂuorescence microscope. The merged image shows that 7ZFMyt1-Myc immunoreactivity appears as
speckles within the nucleus, suggestive of an association of NZF-2b/7ZFMyt1 with a function that is spatially segregated into discrete nuclear domains, similar to the sites of active
transcription (scale bar, 20 μm). (C) Sections were double immunostained with antibodies against NeuN (red) andwith anti-Myt1 antibodies against native NZF-2b/7ZFMyt1 protein
(green) that label both the endogenous and the ectopic protein. Sections were visualized with 100× magniﬁcation under a ﬂuorescence microscope. The merged image shows that
NZF-2b/7ZFMyt1 immunoreactivity appears mostly restricted within the nucleus, suggestive of an association of NZF-2b/7ZFMyt1 with the sites of active transcription (scale bar,
20 μm). (D) Sections were double immunostained with antibodies against GFAP (red) and with anti-Myc antibodies for detecting Myc-tagged, ectopic NZF-2b/7ZFMyt1 protein
(green) and visualized with 100x magniﬁcation under a ﬂuorescence microscope. The merged image shows that NZF-2b/7ZFMyt1-Myc immunoreactivity is not colocalized in glial-
positive cells (scale bar, 20 μm). (E) Sections were double-stained with antibodies against NZF-2b/7ZFMyt1 protein (red) and counterstained with nuclei staining Hoechst 33342
(blue) and visualized with 40× magniﬁcation under a ﬂuorescence microscope. The merged image shows that all NZF-2b/7ZFMyt1 immunoreactivity is colocalized to the nuclei,
whereas not all nuclei show immunoreactivity to NZF-2b/7ZFMyt1 (scale bar, 20 μm). (F) Sections were double-stained with antibodies against NZF-2b/7ZFMyt1 protein (red) and
counterstained with anti-Myc antibodies for detecting Myc-tagged, ectopic NZF-2b/7ZFMyt1 protein (green) and visualized with 63× magniﬁcation under a ﬂuorescence
microscope. The merged image shows that NZF-2b/7ZFMyt1 immunoreactivity is colocalized to the Myc tag labeling (scale bar, 20 μm). (G) Low-magniﬁcation light microscopy for
expression of NZF-2b/7ZFMyt1-Myc in the NAc. Sections were stained with anti-Myc antibodies and revealed by HRP-DAB (brown). Pictures were taken at 2.5× magniﬁcation.
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treatment paradigm and can be inﬂuenced by gene expression
changes in the reward circuitry (Nestler, 2000). Selective induction
of NZF-2b/7ZFMyt1 expression in the NAc signiﬁcantly decreases
an animal's responsiveness to the locomotor-activating effects of
cocaine, whereas local silencing of NZF-2b/7ZFMyt1 results in hyper-
locomotion. Similar observations have been described with over-
expression of other genes, e.g., the D3R DA receptor (Bahi et al., 2005),
and may be due to local compensatory mechanisms following drug
injections (Kalivas and Nakamura, 1999). These results indicate that
NZF-2b/7ZFMyt1 may mediate some of the persistent neural and
behavioral plasticity that accompanies chronic drug exposure.
Continuous cocaine administration produces a rapid sensitization
that is lost over the course of the treatment period (Nestler, 2000).
Behavioral sensitization arise from neuroadapations in multiple brain
nuclei (Vanderschuren and Kalivas, 2000) Our results showing
changes in NZF-2b/7ZFMyt1 expression resulting in apparent co-
caine-induced sensitization in the ﬁrst session (session A) but not
in subsequent sessions indicate the differential involvement of the
accumbens vs. other brain regions in the induction or expression of
cocaine sensitization. Moreover the lesser degree of sensitization
observed after NZF-2b/7ZFMyt1 knock-down indicates a ceiling effect
as the initial cocaine-induced locomotion was already strong enough
that further increase was probably not possible. Tolerance and
sensitization to the locomotor-activating effects of cocaine can exist
simultaneously, since they are mediated by separate mechanisms
(Izenwasser and French, 2002). Our results show that NZF-2b/
7ZFMyt1 might be playing an important role in governing the
animal′s responsiveness in these disparate mechanisms.
Interestingly we observed that NZF-2b/7ZFMyt1 overexpression
mediates increased expression of the transcription factors NAC1 and
REST1 (RE1-silencing transcription factor-1) in the NAc, which can
account for the decreased sensitivity to cocaine's rewarding effects.
NAC1 is a cocaine-regulated POZ/BTB protein that is induced by
cocaine selectively in the NAc and that interacts with histone
deacetylases HDAC3 and HDAC4 (Korutla et al., 2005, 2007). The
other factor affected by NZF-2b/7ZFMyt1, REST1, is a transcriptional
repressor that represses neuronal gene transcription and is required
for the acquisition of the differentiated functional neuronal pheno-
type during early development (Armisen et al., 2002). REST1 targets
genes that are expressed in neurons (Hohl and Thiel 2005) and
silences transcription of numerous neuron-speciﬁc genes in non-
neuronal cells via recruitment of co-repressor complexes, Co-REST,
Sin3A, HDAC1 and HDAC2, thus strongly affecting chromatin re-
modeling (Belyaev et al., 2004), to maintain a repressive chromatin
environment in neural stem cells (Greenway et al., 2006). Induction of
REST1 following NZF-2b/7ZFMyt1 expression after chronic cocaine
may be an important factor for behavioral and cognitive alterations
observed upon drug administration. Together NZF-2b/7ZFMyt1-
triggered expression of NAC1 and REST1 might provide mechanistic
insight into how drugs of abuse can direct chromatin-modifying
enzymes to speciﬁc genes. Indeed cocaine regulation of chromatin-
modifying enzymes is currently considered to play a central function
in shaping the addicted state (Tsankova et al., 2007). Complex epi-
genetic mechanisms which regulate gene activity have long-lasting
effects within mature neurons.
Our ﬁndings that NZF-2b/7ZFMyt1 induces the expression of REST
is supported by earlier studies showing that NZF-2b/7ZFMyt1
inhibits the expression of MeCP2 (Liu and Francke, 2006), which in
turn may repress REST and CoREST expression (Abuhatzira et al.,
2007). MeCP2 is a multifunctional protein involved in the modula-
tion of chromatin structure and in alternate splicing mechanisms.
NZF-2b/7ZFMyt1-binding sites are present in the MECP2 promoter,
speciﬁcally between −553 and −681 as well as in enhancers F11
and F21 and silencer F13 (Liu and Francke, 2006), and thus NZF-2b/
7ZFMyt1 may be part of a complex that keepsMECP2 expression low.
Furthermore elevated levels of REST and CoREST (in the brain of Rett
Fig. 5. Effect of NZF-2b/7ZFMyt1 expression and silencing in the Nucleus Accumbens
(NAc) on the mRNA levels of REST1, NAC1 and BDNF. Quantiﬁcation of REST1 (A), NAC1
(B) and BDNF (C) transcript levels by qRT-PCR from rats (n= 9) bilaterally injected into
the NAc with either lenti-7ZFMyt1 alone, lenti-7ZFMyt1 in combination with a mix of
three lenti-7ZFMyt1 siRNAs, a mix of three lenti-7ZFMyt1 siRNAs alone, or lenti-GFP
(see Methods). Samples were retrieved at the end of behavioral analysis (locomotor
activity) from animals fed either in the presence or in absence of doxycycline. 24 h
after the last injection, animals were sacriﬁced by decapitation and the NAc was micro-
dissected and used for total RNA isolation, cDNA preparation and qRT-PCR. Expression
levels were calculated relative to cyclophilin-D or β-actin. Overexpression of NZF-2b/
7ZFMyt1 led to an increase in expression levels of REST1 (A) and NAC1 (B) and to
a decrease in expression levels of BDNF (C). Doxycycline regimen that inhibits
ectopic NZF-2b/7ZFMyt1 expression results in a signiﬁcant decrease in REST1 (A) and
NAC1 levels (B), but increases BDNF levels (C). ⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001
represent values signiﬁcantly different from lenti-GFP injected rats, and +Pb0.05;
++Pb0.01; +++Pb0.001 represent values signiﬁcantly different from lenti-7ZFMyt1
injected rats, by two-way ANOVA, Bonferroni post hoc tests.
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syndrome patients and in MeCP2 deﬁcient mice) results in down-
regulation of BDNF, apparently by their binding to the RE1 element
located between the ﬁrst two promoters of the BDNF gene. Several
studies described the crucial function of BDNF and TrkB in cocaine
reward and relapse (Kalivas and O'Brien, 2008; Nestler 2000;
Thomas et al. 2008; Bahi et al., 2008). Interestingly, the NTRK2
gene that encodes TrkB, the BDNF receptor, was overexpressed in
MeCP2 deﬁcient human and mouse brains either directly or as an
attempt to compensate for BDNF deﬁciency (Abuhatzira et al., 2007).
Our present ﬁnding implicate that NZF-2b/7ZFMyt1 plays an
important role in induction of REST leading to downregulation of
BDNF. Indeed we observe that NZF-2b/7ZFMyt1 overexpression leads
to BDNF suppression. In addition, NZF-2b/7ZFMyt1 interacts with
Lingo1 (Llorens et al., 2008), a component of the Nogo receptor
complex that mediates intracellular signaling in response to myelin-
associated inhibitors (MAIs). This interaction is responsible for the
intracellular localization and regulation of transcriptional activity of
NZF-2b/7ZFMyt1, whereby Lingo1 causes cytoplasmic localization of
NZF-2b/7ZFMyt1 (Llorens et al., 2008) and transcriptional inactiva-
tion. Interestingly BDNF induces expression of Lingo 1 (Trifunovski
et al., 2004). We propose a model wherein chronic cocaine exposure
results in gradual accumulation of NZF-2b/7ZFMyt1 in the NAc
(Fig. 6), where a dynamic regulation between NZF-2b/7ZFMyt1 and
BDNF might determine key events in the reward pathway. Thus
Fig. 6.Model based on the ﬁndings of NZF-2b/7ZFMyt1 pathway in chronic cocaine administration. The transcriptional activity of NZF-2b/7ZFMyt1 regulates expression of related
factors, including many of the cocaine-regulated genes and of myelin-related genes, but these effects can possibly be controlled by its inactivation and cytoplasmic translocation
upon binding to the effector Lingo1. Under normal homeostatic conditions, NZF-2b/7ZFMyt1 is poorly expressed in the mesolimbic dopaminergic pathway, whereas under chronic
drug treatment (A), cocaine induces strong expression of NZF-2b/7ZFMyt1, which modulates expression of several genes: mainly it induces expression of REST1 and NAC1 (and also
of myelin-related genes, e.g., PLP1) and it represses expression of BDNF and of MeCP2, which itself is known to repress expression of REST1. Furthermore REST1 induction in turn is
known to regulate expression of BDNF, which, among other neurotrophic effects, also induces Lingo1, a factor that binds to NZF-2b/7ZFMyt1. This might lead to cytoplasmic
translocation of NZF-2b/7ZFMyt1, yielding to its inactivation. (B) The feedback loop between BDNF and NZF-2b/7ZFMyt1 might determine the state of tolerance or addiction to the
exposed psychostimulant. Lentivirus-mediated overexpression of NZF-2b/7ZFMyt1 strongly inhibits BDNF expression — either directly or/and by stronger induction of REST1
expression (see text for details).
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NZF-2b/7ZFMyt1 expression might be involved in titrating behav-
ioral responses to psychostimulants through a complex series of
downstream transcriptional events, involving the induction (NAC1 &
REST1 expression) or repression (BDNF expression) of several target
genes. Future studies aimed at identifying the factors that deter-
mine NZF-2b/7ZFMyt1 effects on target genes, might shed light on
this complex pathway. Clearly NAC1 and REST1 may be just two of
the many targets regulated by NZF-2b/7ZFMyt1 in the NAc. Based
on these observations, our study sheds light on the little known
pathway in this brain region, which might lead to addiction-like
behavior.
In conclusion, we show that NZF-2b/7ZFMyt1may be an important
factor involved in phenotypic changes induced by chronic cocaine
administration. So far it has been difﬁcult to identify the molecular
mechanisms that underlie such stable changes in gene expression.
Our observations on the functional implication of NZF-2b/7ZFMyt1
provides an alternate insight into the basic transcriptional and
epigenetic mechanisms involved in the desensitization of genes in
drug administration, which may facilitate the development of more
successful drug treatment strategies.
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